FDA Advisory Committee To Review Lux Biosciences' Uveitis Candidate Luveniq™

Links shared publicly online about this topic.

1,173
total visits

FDA Advisory Committee To Review Lux Biosciences' Uveitis Candidate Luveniq™

Lux Biosciences, Inc. today announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review its New Drug Application

View full resource at medicalnewstoday.com

Tags: Dermatology, Drug, FDA, Ophthalmology

Most Recently Shared on May 13, 2010 at 9:43 am By:

Oral Health OW

FDA Advisory Committee To Review Lux Biosciences' Uveitis Candidate Luveniq: Lux Biosciences, Inc. today announced... http://mnt.to/f/3Cx6

2 years ago...

Retweet

Favorite

Also Shared By:

MNT Eye Health

MNT Drug Approvals

Infectious Disease

FDA Dermatology and Ophthalmology Drugs Advisory Committee to review Lux Biosciences' Luveniq NDA

news-medical.net — “Lux Biosciences, Inc. today announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review its New Drug Application (NDA) for Luveniq" (oral voclosporin) for the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye on June 28, 2010.” View full resource at news-medical.net